Testosterone therapy - What, when and to whom?

Aging Male

Volumn 7, Issue 4, 2004, Pages 319-324

  Jockenhovel F ^a  

^a Evangelisches Krankenhaus Herne   (Germany)

Author keywords

Hypogonadism; Testosterone deficiency; Testosterone supplementation; Testosterone transdermal patch; Testosterone undecanoate injections; Testosterone containing gel

Indexed keywords

ANDROSTANOLONE; CHYLOMICRON; ESTRADIOL; FOLLITROPIN; GONADORELIN; GONADOTROPIN; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

AGING; ANDROGEN THERAPY; ANORCHIA; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERECTILE DYSFUNCTION; FIRST PASS EFFECT; GEL; GONADOTROPIN RELEASE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPITUITARISM; HYPOTHALAMUS FUNCTION DISORDER; INJECTION; KLINEFELTER SYNDROME; LONG TERM CARE; MOOD DISORDER; PATIENT SATISFACTION; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SKIN MANIFESTATION; SYMPTOM; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE;

AGE FACTORS; ANDROGENS; ANDROPAUSE; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGONADISM; MALE; PATIENT SELECTION; TESTOSTERONE;

EID: 11244283494     PISSN: 13685538     EISSN: None     Source Type: Journal    
DOI: 10.1080/13685530400016557     Document Type: Conference Paper

References (18)

1. Morales A. Andropause (or symptomatic late-onset hypogonadism): facts, myths and controversies. Aging Male 2004;7:297-303
2. Hameed A, Brothwood T, Bouloux P. Delivery of testosterone replacement therapy. Curr Opin Investig Drugs 2003;4:1213-19
3. Swerdloff RS, Wang C, Cunningham GR, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-10
4. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-53
5. Wang C, Cunningham D, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89:2085-98
6. Jockenhövel F. Male Hypogonadism. Bremen: UNI-MED Verlag AG, 2004
7. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2002;5:74-86
8. Schürmeyer T, Nieschlag E. Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 1984;7:181-7
9. Köhn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol 2003;21: 311-31
10. Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol 2003;21: 311-15
11. Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male 2003;6:86-93
12. Morales A, Johnston B, Heaton JP, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 1997;157:849-54
13. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study. J Clin Endocrinol Metab 1996;81: 1832-40
14. Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol 1999;50:57-62
15. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J Clin Endocrinol Metab 2000;85:964-9
16. Minnemann T, Christoph A, Hübler D, Ernst M, Oettel M, Krone W, Jockenhövel F. Long-term efficacy of intramuscular testosterone undecanoate in hypogonadal men. Proc Am Soc Endocr 2001;83rd Annual Meeting:P2-472
17. Schubert M, Bullmann C, Oettel M, Hübller D, Krone W, Jockenhövel F. Intramuscular application of testosterone undecanoate - a novel mode of androgen substitution with sustained duration. Exp Clin Endocrinol Diabetes 1999;107(Suppl 1):S62
18. Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone-undecanoate -pharmacokinetic aspects of a novel testosterone formulation during long term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004: in press